JUNE Medical’s Galaxy II™ Used In Military Hospitals

JUNE Medical is proud to announce that it is supplying a U.S. military hospital with its award-winning Galaxy II self-retaining surgical retractor range, including the innovative Galaxy II LUX Connect light.

This is a great opportunity for JUNE to show its support to military and Veteran Affairs (VA) medical centers, by equipping them with the best-in-class surgical retractors.

The Galaxy II range was first used by world-class surgeons at Wilford Hall Ambulatory Surgical Center – the U.S. Air Force’s flagship medical facility in Texas – for an open inguinal hernia repair. The unique and adaptable design of the retractor, and the addition of the bifurcated light source, were invaluable for providing a clear visualization of cavities. The Galaxy II includes a novel CAM lock system that allows simple one-handed adjustments and reduces the number of staff required to assist, giving surgeons greater control over their surgical field. These same benefits can be applied to a variety of procedures, including ENT, colorectal, orthopedic, gynecologic, and other open surgeries. JUNE is hoping to expand this success across the 54 military hospitals and 152 VA facilities in the U.S., to provide serving soldiers, veterans, and their families with the highest quality surgical equipment.

Emanuel Adam, Director of Policy & Trade at BritishAmerican Business commented: “BAB is thrilled to witness yet another milestone in the growth journey of JUNE Medical, as this company continues to deliver life-changing British innovation to hospitals and surgeons across the United States. Today’s announcement is a fine example of how innovative businesses such as JUNE Medical are the backbone of the transatlantic trade and investment success story, to the benefit of patients and local communities across both countries.”

Laurie Spicer, International Trade Advisor at the Department for International Trade, commented: “I have not only had the pleasure of supporting June Medical with their launch in the USA but have been extremely impressed with their courage, commitment and dedication to delivering their award winning Galaxy retractor to U.S. medical facilities. They are an incredible team who work tirelessly to make sure they deliver an exceptional product with the best service at the best price.”

To learn more about the Galaxy II self-retaining retractor, visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”